Did Caris Life Sciences beat or miss consensus estimates last quarter?

What guidance did Caris Life Sciences's management provide for the next earnings period?

What does Caris Life Sciences do and what are its main business segments?

What were the key takeaways from Caris Life Sciences’s earnings call?

What is Caris Life Sciences's latest dividend and current dividend yield?

What is Caris Life Sciences's gross profit margin?

What is the revenue and EPS growth rate for Caris Life Sciences year over year?

What factors drove the changes in Caris Life Sciences's revenue and profit?

- **Revenue Supercharge**: 113% YoY growth ($720M+ 2025) driven by 121% mol prof services, 18% pharma R&D.
- **AI-Powered Margins**: 68% gross margin (Q3 2025) vs 43.7% 2024, ASPs up 15% tissue, 18% blood.
- **Pipeline Breakthroughs**: MRD 96% sensitivity, whole genome early detection enrolling 16,000+ subjects.
- **Cash Flow Dominance**: $55M free cash flow,3Q25, balance sheet $760M.
- **2025 Outlook**: 21-22% clinical growth, 68%+ gross margin target.
- **Strategic Wins**: 80%+ MRD accuracy, 18% blood ASP growth.
- **Pipeline Momentum**: Early detection, MRD, pharma R&D expansion.
- **Execution Excellence**: 68% gross margin, 15% ASP expansion.
- **Future Growth**: 2025+ pipeline with whole genome sequencing, MRD commercialization.

**【CEO Summary Section】**
- CEO highlighted Q3 2025 revenue growth of 113% YoY, driven by molecular profiling services ($207.6M, +121% YoY) and pharma R&D ($9.2M, +18.3% YoY). 
- Emphasized AI-driven early detection pipeline progress, with ACHIEVE-1 whole genome study enrolling 16,000 subjects and ACHIEVE-2 targeting 25,000 high-risk individuals.
- Gross margin improved to 68% (Q3 2025) from 43.7% (Q2 2025), with ASPs rising to $3,600+ for tissue and $2,377 for blood.

**【CFO Financial Commentary】**
- GAAP net income $24.3M, non-GAAP EPS $1.08 vs. $0.85 prior guidance.
- Free cash flow $55.3M, up 125% YoY, with balance sheet strength at $760M.
- 2025 guidance updated to $720-730M revenue (+75% YoY), 21-22% clinical case volume growth.
- 2025 gross margin target 68%+ vs. 43.7% 2024, driven by ASP expansion and lab efficiency gains.

**【Q&A Highlights】**
- MRD pipeline progress: Colorectal cancer MRD solution showing 96.3% sensitivity vs. 80%+ recurrence prediction accuracy.
- Blood ASPs up 18% Q3, tissue ASPs up 15% YoY, with 2025 ASP guidance $3,600+ tissue, $2,377 blood.
- Early detection pipeline: Whole genome sequencing for early cancer detection in development, with 18,600 subjects enrolled in ACHIEVE-1.
- Pharma R&D services up 18.3% YoY, with multi-year partnerships in pipeline.
- 2025 gross margin target 68%+, up from 43.7% 2024

Caris Life Sciences, Inc. (CAI) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 2025 revenue up 81% YoY to $181.4 million, driven by 86% growth in molecular profiling and 49% in pharma R&D.
- **ASP Leap**: ASP rose 52% YoY to $3,256, with 78% of tissue cases on high-margin MI Cancer Seek.
- **Profitability Breakthrough**: First positive adjusted EBITDA ($16.7M) and free cash flow ($5.9M) in Q2, reversing prior-year cash burn.
- **Pipeline Momentum**: MRD monitoring for CRC, early breast cancer detection, and heme assays in development; FDA submissions planned.
- **Market Leadership**: 30% CGP penetration, with AI tools reclassifying 704 cases and altering therapy in 86% of instances.

**【CEO Summary Section】**
- Caris Life Sciences reported Q2 2025 revenue of $181.4 million, up 81% YoY, driven by 86% growth in molecular profiling and 49% growth in pharma R&D services.
- Clinical case volumes reached 50,000 profiles (22% YoY), with ASP increasing to $3,256 (52% YoY) due to CMS rate updates for MI Cancer Seek and adoption of whole exome/transcriptome assays.
- Gross margin improved to 62.7% (from 37.5% YoY), reflecting operational efficiency and higher-margin MI Cancer Seek volumes (78% of tissue cases in Q2).
- Achieved positive adjusted EBITDA ($16.7 million) and free cash flow ($5.9 million), marking a significant turnaround from prior-year cash burn.
- Pipeline progress includes MRD monitoring for colorectal cancer, early breast cancer detection, and heme assays, with FDA submissions planned.

**【CFO Financial Commentary】**
- Total revenue guidance for FY 2025: $675-685 million (64-66% YoY growth), with clinical case volume growth expected at 19-21%.
- Pharma R&D revenue grew 49% to $18.5 million, driven by long-term partnerships and pipeline expansion.
- Operating expenses increased 26% YoY, primarily due to IPO-related stock compensation ($23.8 million).
- Free cash flow guidance for FY 2025 focuses on controlling burn while investing in growth initiatives.

**【Q&A Highlights】**
- **ASP Growth**: 78% of tissue cases now on MI Cancer Seek, with CMS rate of $8,455 driving ASP to $3,256. Commercial payer coverage expanded to 170 million lives (including Medicare).
- **Pipeline Strategy**: MRD monitoring for CRC targeting MolDX submission; early breast cancer detection to launch as self-pay; heme assays (myeloid disorders) expected to leverage existing reimbursement frameworks.
- **Competitive Position**: 30% market penetration for CGP, with differentiated AI tools (e.g., GPS AI) reclassifying 704 cases and altering therapy in 86% of instances.
- **Capital Deployment**: No M&A plans; focus on organic growth and pipeline development with $723 million in cash post-IPO.

CAI

CAI fundamentals

Earnings Call

You can ask Aime